Moraxella Bacteremia: A Patient‑Centred Medical Guide

Overview

Moraxella bacteremia is a bloodstream infection caused by bacteria of the genus Moraxella, most commonly Moraxella catarrhalis. Although M. catarrhalis is best known for causing ear infections, sinusitis, and bronchitis, it can occasionally enter the bloodstream and lead to a systemic infection.

Who it affects: Moraxella bacteremia is relatively rare and typically occurs in adults with underlying health problems. The highest risk groups are:

• Elderly individuals (≥ 65 years)
• Patients with chronic lung disease (COPD, bronchiectasis)
• People with immunosuppression (cancer chemotherapy, organ transplant, HIV)
• Individuals with recent head/neck surgery or invasive procedures

Prevalence: In the United States, M. catarrhalis accounts for <1–2 % of all bloodstream isolates reported to the National Healthcare Safety Network (NHSN) (CDC, 2023). Worldwide, the incidence is estimated at roughly 0.5–1 case per 100,000 population per year, with higher rates in long‑term care facilities.¹

Symptoms

Because the infection spreads through the blood, symptoms are often systemic and may mimic other types of sepsis. Common manifestations include:

• Fever or chills – often sudden onset, temperature >38 °C (100.4 °F).
• Generalized weakness or fatigue – may be profound, especially in older adults.
• Rapid heart rate (tachycardia) – >100 beats per minute.
• Rapid breathing (tachypnea) – >20 breaths per minute or shortness of breath.
• Low blood pressure (hypotension) – a sign of septic shock in severe cases.
• Confusion or altered mental status – particularly in the elderly.
• Skin manifestations – petechiae, purpura, or mottled rash.
• Joint pain or swelling – may indicate septic arthritis secondary to bacteremia.
• Urinary symptoms – dysuria or flank pain if the bacteria seed the kidneys.
• Chest pain or cough – suggests concurrent pneumonia, a frequent source of the bacteria.

Symptoms may develop within hours to a few days after the bacteria enter the bloodstream. In immunocompromised patients, classic signs like fever can be muted, making vigilance essential.

Causes and Risk Factors

How the infection starts

Moraxella catarrhalis is a Gram‑negative diplococcus that normally colonises the upper respiratory tract. Infection occurs when the bacteria breach the mucosal barrier and gain access to the bloodstream. Common pathways include:

• Respiratory source – severe sinusitis, bronchitis, or pneumonia.
• Otitis media or mastoiditis – especially in children, though bacteremia is rare.
• Invasive procedures – bronchoscopy, intubation, or nasal surgeries.
• Dental extractions or poor oral hygiene – can seed bacteria via gingival vessels.

Risk factors

• Advanced age (immune senescence)
• Chronic obstructive pulmonary disease (COPD) or other lung diseases
• Immunosuppression (corticosteroids, biologics, chemotherapy)
• Diabetes mellitus
• Alcoholism or smoking (damages respiratory epithelium)
• Recent hospitalization or residence in a long‑term care facility
• Presence of indwelling devices (central lines, urinary catheters)

Diagnosis

Diagnosing Moraxella bacteremia requires a combination of clinical suspicion and laboratory testing.

Blood cultures

• Two sets of aerobic and anaerobic cultures drawn from separate sites are recommended before starting antibiotics.
• On Gram stain, M. catarrhalis appears as Gram‑negative, kidney‑shaped diplococci.
• Typical growth on chocolate or blood agar yields smooth, opaque colonies that are oxidase‑positive.

Additional laboratory studies

• Complete blood count (CBC) – often shows leukocytosis or leukopenia.
• Serum lactate – elevated levels (>2 mmol/L) suggest sepsis.
• Inflammatory markers – C‑reactive protein (CRP) and procalcitonin may be markedly high.
• Renal and liver panels – to assess organ involvement.

Imaging (if source unclear)

• Chest X‑ray or CT scan – evaluate for pneumonia or lung abscess.
• Head/neck CT or MRI – if sinusitis, mastoiditis, or intracranial involvement is suspected.
• Ultrasound of abdomen – to rule out hepatic or splenic abscesses.

Antibiotic susceptibility testing

Because M. catarrhalis commonly produces β‑lactamase, susceptibility testing guides therapy. Disk diffusion or automated systems (VITEK, BD Phoenix) are standard.

Treatment Options

Prompt antimicrobial therapy is the cornerstone of treatment. The choice of drug, duration, and need for adjunctive measures depend on severity, source, and patient comorbidities.

First‑line antibiotics

• Third‑generation cephalosporins (e.g., ceftriaxone 1‑2 g IV every 24 h) – effective against most β‑lactamase‑producing strains.
• Fluoroquinolones (e.g., levofloxacin 750 mg PO/IV daily) – useful for oral step‑down therapy.
• Macrolides (azithromycin 500 mg IV/PO daily) – alternative in penicillin‑allergic patients, though resistance is rising.

Alternative agents

• Amoxicillin‑clavulanate (if susceptibility confirmed)
• Carbapenems (e.g., meropenem) – reserved for severe sepsis or multidrug‑resistant isolates.

Duration of therapy

Typical treatment length is 10–14 days for uncomplicated bacteremia. If a deep‑seated focus (e.g., endocarditis, osteomyelitis) is identified, 4–6 weeks may be required.

Supportive care

• Intravenous fluid resuscitation to maintain perfusion.
• Vasopressors (norepinephrine) for septic shock not responsive to fluids.
• Oxygen supplementation or mechanical ventilation if respiratory failure occurs.
• Source control – drainage of abscesses, removal of infected catheters, or surgical debridement when indicated.

Lifestyle & adjunct measures

• Adequate rest and hydration during recovery.
• Smoking cessation – improves mucosal immunity.
• Nutrition optimisation (protein‑rich diet) to support immune function.

Living with Moraxella Bacteremia

Even after successful treatment, patients often wonder how to return to normal life and prevent recurrence. Below are practical tips.

• Follow‑up appointments – schedule blood tests and clinical review 1‑2 weeks after completing antibiotics to confirm clearance.
• Medication adherence – never skip doses; missing even a few pills can allow resistant organisms to emerge.
• Vaccinations – stay current on influenza, pneumococcal (PCV15/20 and PPSV23), and COVID‑19 vaccines, which reduce respiratory infections that can precipitate bacteremia.
• Hand hygiene – wash hands with soap for 20 seconds, especially after coughing or handling respiratory secretions.
• Monitor for new symptoms – fever, chills, shortness of breath, or unexplained pain should prompt a call to your clinician.
• Manage chronic conditions – tightly control diabetes, COPD, and heart failure to lower infection risk.
• Physical activity – moderate exercise (e.g., walking 30 min most days) improves lung capacity and immunity.

Prevention

Because most cases arise from a respiratory source, preventing upper‑airway infections is key.

• Vaccinate against influenza and pneumococcus annually or as recommended.
• Quit smoking and avoid exposure to second‑hand smoke.
• Good oral hygiene – brush twice daily, floss, and attend dental check‑ups.
• Prompt treatment of respiratory infections – seek medical care early for persistent cough, sinus pain, or ear discharge.
• Proper care of indwelling devices – follow sterile technique when handling catheters or central lines.
• Hand hygiene in health‑care settings – health‑care workers should use alcohol‑based hand rubs before patient contact.
• Nutrition and sleep – adequate protein, vitamins (A, C, D, zinc), and 7‑9 hours of sleep each night support immune defenses.

Complications

If left untreated or inadequately treated, Moraxella bacteremia can progress to serious, life‑threatening conditions:

• Septic shock – widespread vasodilation, organ hypoperfusion, and high mortality.
• Endocarditis – infection of heart valves, requiring prolonged antibiotics or surgery.
• Metastatic abscesses – in brain, liver, spleen, or bone.
• Acute respiratory distress syndrome (ARDS) – severe lung inflammation causing respiratory failure.
• Acute kidney injury – from hypotension or direct bacterial toxin damage.
• Coagulopathy/DIC – abnormal clotting that can lead to bleeding.

Mortality rates for Moraxella bacteremia are reported at 8–15 % in older adults with comorbidities, rising to >30 % in septic shock scenarios.²

When to Seek Emergency Care

---

References:
1. Centers for Disease Control and Prevention. National Healthcare Safety Network (NHSN) Annual Report, 2023.
2. K. H. Lee et al., “Outcomes of Moraxella catarrhalis bacteremia in adults,” Journal of Clinical Microbiology, vol. 60, no. 4, 2022.
3. Mayo Clinic. “Sepsis,” 2024. https://www.mayoclinic.org.
4. CDC. “Antibiotic Resistance Threats in the United States,” 2023.
5. Cleveland Clinic. “Bacterial Bloodstream Infections,” 2024.